Scribd
Upload
150 views18 pages

Precision Medicine Oncology

Dr. Aminudin Rahman Mohd Mydin graduated from the University of Malaya in 1999 and obtained further training in clinical oncology in Ireland and Canada. He received additional training in advanced radiotherapy techniques for cancers like prostate, breast and head and neck. He has worked as a consultant oncologist in hospitals in Malaysia and was an associate professor at UiTM. Currently he is a consultant oncologist at KPJ Damansara Specialist Hospital and has published articles in international oncology journals.

Uploaded by

aminudinrahman
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
150 views18 pages

Precision Medicine Oncology

Dr. Aminudin Rahman Mohd Mydin graduated from the University of Malaya in 1999 and obtained further training in clinical oncology in Ireland and Canada. He received additional training in advanced radiotherapy techniques for cancers like prostate, breast and head and neck. He has worked as a consultant oncologist in hospitals in Malaysia and was an associate professor at UiTM. Currently he is a consultant oncologist at KPJ Damansara Specialist Hospital and has published articles in international oncology journals.

Uploaded by

aminudinrahman
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
You are on page 1/ 18

SPEAKER’S PROFILE

DR AMINUDIN RAHMAN BIN MOHD MYDIN


MBBS (Malaya) FRCR (UK) AM (Mal) Fellow Radiation Oncology (Canada)
Consultant Clinical & Radiation Oncologist, KPJ Damansara Specialist Hospital

Dr Aminudin Rahman Mohd Mydin graduated from the University of Malaya in 1999. He did his postgraduate
training in Clinical Oncology in St Luke’s Hospital, Dublin, Ireland, the National Cancer Centre in Ireland. He
obtained the Fellowship of the Royal College of Radiologists (UK) in Clinical Oncology in 2006. He continued his
training and research in radiation oncology as a Clinical Research Fellow in the British Columbia Cancer Agency
(BCCA) / University of British Columbia (UBC), Victoria and Vancouver, British Columbia, Canada (2007-2008).
Here, he received training in advanced radiotherapy techniques like IMRT/IGRT in prostate cancer, breast cancer
and head and neck cancers.

Later, he was appointed Consultant Clinical Oncologist in the Department of Radiotherapy & Oncology, Kuala
Lumpur Hospital (HKL), the National Tertiary Referral Centre of Malaysia. In late 2011, he was appointed an
Associate Professor of Medicine (Oncology) in the Faculty of Medicine, University Technology MARA (UiTM),
before joining KPJ Johor Specialist Hospital in 2012. Recently, he joined KPJ Damansara Specialist Hospital as a
Resident Consultant Clinical Oncologist.

He has published articles in international peer-reviewed oncology journals including in prostate cancer, and
presented at major international oncology meetings (ASTRO & CARO). He is an international member of the
American Society for Therapeutic Radiology and Oncology (ASTRO), life members of Malaysian Medical
Association (MMA) and Malaysian Oncological Society (MOS) and member of College of Radiology, Academy of
Medicine Malaysia. He was also the Treasurer, National Cancer Society Malaysia, Johor Branch.
Precision Medicine
In Oncology:
Lung Cancer
Precision Cancer Medicine using NGS technology
Precision Cancer Medicine using NGS technology
Erlotinib in EGFR+ Lung Cancer
Crizotinib in ALK+ Lung Cancer
Skin side effects of Targeted Therapy for Lung Cancer
Immunotherapy for Lung Cancer
Immunotherapy for Lung Cancer – PD-L1 IHC test
Immunotherapy for Lung Cancer
TABLE :Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer
FDA DRUG NAME DRUG TYPE
APPROVAL
FDA approved Keytruda PD-1 inhibitor
(pembrolizumab)
Tecentriq PD-L1 inhibitor
(atezolizumab)
Opdivo PD-1 inhibitor
(nivolumab)
Used only for patients (Imfinzi) PD-L1 inhibitor
with lung cancer who are Durvalumab
in clinical trials (Bavencio) PD-L1 inhibitor
Avelumab
Yervoy CTLA-4 inhibitor
(Ipilimumab)
Tremelimumab CTLA-4 inhibitor
Improvements of Survival of Advanced Lung Cancer Patients
in era of Molecular Oncology
THANK YOU !

You might also like